Invisible Affliction: The Overlooked Burden of Adenomyosis among Indian Women

Recent epidemiological surveys conducted within the Republic of India have estimated that approximately one in ten women of reproductive age endure the chronic uterine condition known as adenomyosis, a disorder whose pathological hallmark involves the ectopic presence of endometrial tissue within the myometrial wall, thereby precipitating a constellation of dysmenorrhea, menorrhagia, and pelvic discomfort. Nevertheless, testimonies collected from affected individuals and their families consistently indicate that the severity of their pain and functional limitation is frequently dismissed as merely psychosomatic by practitioners entrenched within overburdened public hospitals, thereby engendering a pernicious cycle of underdiagnosis and therapeutic neglect.

The Ministry of Health and Family Welfare, in statements issued subsequent to parliamentary queries, professes unwavering commitment to augmenting diagnostic capabilities through the dissemination of ultrasonography guidelines, yet the implementation timetable remains nebulous, with resources ostensibly allocated to metropolitan tertiary centres while peripheral primary health units continue to lack both trained sonographers and requisite equipment. Consequently, women residing in rural districts are compelled to traverse considerable distances, often incurring substantial out‑of‑pocket expenditures for privately procured magnetic resonance imaging, an exigency that starkly contravenes the constitutional guarantee of equitable access to health care services.

In addition to the evident medical lacunae, the paucity of comprehensive health education within school curricula and community outreach programmes perpetuates a societal stigma surrounding menstrual disorders, thereby discouraging young women from seeking timely medical counsel and reinforcing gendered disparities entrenched within the public health architecture. Furthermore, municipal authorities tasked with provisioning sanitary infrastructure frequently prioritize competing civic projects, leaving numerous urban slums bereft of functional public toilets equipped with adequate disposal mechanisms, a circumstance that aggravates the symptomatic burden of adenomyosis by exposing sufferers to unsanitary conditions and heightened infection risk.

Legislative measures such as the National Health Mission’s Reproductive Health Component have yet to integrate specific provisions for adenomyosis screening or subsidised treatment pathways, a legislative omission that reflects broader systemic inertia and a reluctance to allocate budgetary allocations for conditions perceived as lacking immediate mortality impact. As a result, civil society organisations, while endeavouring to lobby for inclusion of the disorder within the ambit of the Women’s Health Index, encounter procedural bottlenecks characterised by protracted data‑submission requirements and the absence of a transparent grievance redressal mechanism, thereby compounding the disenfranchisement of an already vulnerable demographic.

In light of the constitutional mandate enshrined in Article 21 guaranteeing the right to health, one must inquire whether the State, by failing to allocate definitive funds for adenomyosis diagnostic services in primary health centres, breaches its statutory duty to provide equitable medical care to all citizens irrespective of gender or socioeconomic status. In addition, the apparent omission of adenomyosis from the procedural checklist of the National Health Policy 2025 raises the pertinent question of whether the Ministry’s reliance upon disease prevalence thresholds neglects the lived realities of a substantial minority, thereby contravening principles of inclusive public‑policy formulation and undermining the very objectives of universal health coverage espoused by the government. Consequently, one must also contemplate whether the existing grievance redressal apparatus, overseen by the Central Health Authority, possesses the requisite statutory power to sanction remedial action against obstetric and gynaecological practitioners who repeatedly discount patient‑reported pain, and whether the absence of such enforcement mechanisms implicates the State in indirect negligence under tortious principles?

Given that the Union Budget for the fiscal year 2026‑27 earmarked a nominal increase in the women’s health tranche yet omitted specific line‑items for adenomyosis research and subsidised treatment, a critical inquiry arises as to whether the parliamentary oversight committees possess the authority, and indeed the willingness, to compel the Ministry to re‑allocate resources in conformity with evidence‑based priority setting principles. Moreover, the persistent absence of a centralized, gender‑disaggregated health information system capable of tracking adenomyosis incidence and treatment outcomes across states compels us to question whether the National Digital Health Mission’s architectural blueprint intentionally sidelines such data out of fiscal expediency, thereby depriving policymakers of the empirical foundation requisite for judicious allocation of scarce medical resources. Finally, considering that affected women are frequently compelled to navigate labyrinthine administrative forms, obtain multiple specialist referrals, and bear substantial indirect costs, one must ask whether the existing procedural safeguards genuinely empower ordinary citizens to demand accountability, or merely constitute a bureaucratic veneer that masks systemic inertia while offering illusory assurances of remedial action?

Published: May 20, 2026

Published: May 20, 2026